Petros Pharmaceuticals, Inc. Operating Cash Flow
Petros Pharmaceuticals, Inc. (PTPI) reported Operating Cash Flow of -$1.65 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-13
- Petros Pharmaceuticals, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$863.86K.
- Petros Pharmaceuticals, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$784.27K.
- Petros Pharmaceuticals, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$933.54K, a 196.70% decline year-over-year.
- Petros Pharmaceuticals, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$1.13M.
- Petros Pharmaceuticals, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$6.73M.
- Petros Pharmaceuticals, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$2.60M.
- Petros Pharmaceuticals, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$7.63M.
- Petros Pharmaceuticals, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$12.80M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$863.86K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$1.65M 10-Q · filed 2026-08-13 | -$2.58M derived: sum of 3 quarters · filed 2026-08-13 | -$3.72M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$784.27K 10-Q · filed 2026-05-13 | -$1.72M derived: sum of 2 quarters · filed 2026-05-13 | -$2.85M derived: sum of 3 quarters · filed 2026-05-13 | -$5.86M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$933.54K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15 | -$2.07M derived: sum of 2 quarters · filed 2026-04-15 | -$5.07M derived: sum of 3 quarters · filed 2026-08-13 | -$6.73M 10-K · filed 2026-04-15 |
| 2025-09-30 | -$1.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$4.14M derived: sum of 2 quarters · filed 2026-08-13 | -$5.80M 10-Q · filed 2025-11-13 | -$4.84M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$3.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$4.67M 10-Q · filed 2026-08-13 | -$3.70M derived: sum of 3 quarters · filed 2026-08-13 | -$4.47M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$1.66M 10-Q · filed 2026-05-13 | -$694.68K derived: sum of 2 quarters · filed 2026-05-13 | -$1.47M derived: sum of 3 quarters · filed 2026-05-13 | -$3.13M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $965.40K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15 | $194.16K derived: sum of 2 quarters · filed 2026-04-15 | -$1.47M derived: sum of 3 quarters · filed 2026-04-15 | -$2.60M 10-K · filed 2026-04-15 |
| 2024-09-30 | -$771.25K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$2.43M derived: sum of 2 quarters · filed 2025-11-13 | -$3.57M 10-Q · filed 2025-11-13 | -$5.83M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$1.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$2.80M 10-Q · filed 2025-08-14 | -$5.06M derived: sum of 3 quarters · filed 2025-08-14 | -$9.10M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$1.13M 10-Q · filed 2025-05-15 | -$3.39M derived: sum of 2 quarters · filed 2025-05-15 | -$7.44M derived: sum of 3 quarters · filed 2025-05-15 | -$8.01M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | -$2.26M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$6.31M derived: sum of 2 quarters · filed 2025-03-31 | -$6.88M derived: sum of 3 quarters · filed 2025-03-31 | -$7.63M 10-K · filed 2025-03-31 |
| 2023-09-30 | -$4.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$4.62M derived: sum of 2 quarters · filed 2024-11-13 | -$5.37M 10-Q · filed 2024-11-13 | -$6.94M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | -$572.07K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$1.32M 10-Q · filed 2024-08-14 | -$2.89M derived: sum of 3 quarters · filed 2024-08-14 | -$4.64M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | -$748.36K 10-Q · filed 2024-05-15 | -$2.32M derived: sum of 2 quarters · filed 2024-05-15 | -$4.07M derived: sum of 3 quarters · filed 2024-05-15 | -$8.27M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | -$1.57M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | -$3.32M derived: sum of 2 quarters · filed 2024-04-01 | -$7.52M derived: sum of 3 quarters · filed 2024-04-01 | -$12.80M 10-K · filed 2024-04-01 |
| 2022-09-30 | -$1.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-15 | -$5.95M derived: sum of 2 quarters · filed 2023-11-15 | -$11.23M 10-Q · filed 2023-11-15 | -$19.53M derived: sum of 4 quarters · filed 2023-11-15 |
| 2022-06-30 | -$4.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$9.48M 10-Q · filed 2023-08-14 | -$17.78M derived: sum of 3 quarters · filed 2023-08-14 | -$18.99M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | -$5.28M 10-Q · filed 2023-05-15 | -$13.58M derived: sum of 2 quarters · filed 2023-05-15 | -$14.79M derived: sum of 3 quarters · filed 2023-05-15 | -$16.69M derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | -$8.30M derived: 10-K 12 month − 10-Q/A 9 month · filed 2023-03-31 | -$9.52M derived: sum of 2 quarters · filed 2023-03-31 | -$11.42M derived: sum of 3 quarters · filed 2023-03-31 | -$11.86M 10-K · filed 2023-03-31 |
| 2021-09-30 | -$1.21M derived: 10-Q/A 9 month − 10-Q 6 month · filed 2022-11-15 | -$3.11M derived: sum of 2 quarters · filed 2022-11-15 | -$3.56M 10-Q/A · filed 2022-11-15 | -$8.08M derived: sum of 4 quarters · filed 2022-11-15 |
| 2021-06-30 | -$1.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | -$2.35M 10-Q · filed 2022-08-12 | -$6.87M derived: sum of 3 quarters · filed 2022-08-12 | -$9.54M derived: sum of 4 quarters · filed 2022-08-12 |
| 2021-03-31 | -$446.58K 10-Q · filed 2022-05-16 | -$4.97M derived: sum of 2 quarters · filed 2022-05-16 | -$7.64M derived: sum of 3 quarters · filed 2022-05-16 | -$13.38M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | -$4.52M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | -$7.19M derived: sum of 2 quarters · filed 2022-03-31 | -$12.93M derived: sum of 3 quarters · filed 2022-03-31 | -$15.31M 10-K · filed 2022-03-31 |
| 2020-09-30 | -$2.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | -$8.41M derived: sum of 2 quarters · filed 2021-11-15 | -$10.78M 10-Q · filed 2021-11-15 | |
| 2020-06-30 | -$5.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | -$8.12M 10-Q · filed 2021-08-16 | ||
| 2020-03-31 | -$2.38M 10-Q · filed 2021-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B |